🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6 results for “bictegravir” Clear

  1. EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, Placebo to BIK/FTC/TAF, islatravir, ulonivirine, MK-8591B, Placebo to 8591B

    Merck Sharp and Dohme

    HIV

    phase 3 small molecule active

    1 trial

  2. LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE,

    Gilead Sciences International Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  3. PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences International Limited

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  4. Placebo to doravirine/ islatravir, MK-8591A, Placebo to bictegravir/ emtricitabine/ tenofovir alafenamide, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  5. Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences International Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  6. Placebo to ISL, Placebo to MK-8507, Placebo to BIC/FTC/TAF, EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, islatravir, ulonivirine

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources